Buena Vista Museum to host annual ‘Spectacular World of Science'
Wind Wolves Preserve to host annual 'Spring Nature Festival'
The event will be filled with hands on activities, live science demonstrations, reptiles and students will present their science fair projects.
All proceeds made from the event will benefit the museum's educational programs.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia
BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced enrollment of the first patient in the Randomized Study of the A uryon Atherecto m y System Used in Combination with Standard B alloon Ang i oplasty Versus S t andard Balloon Angioplasty Alone Treating I nfrapopliteal Lesi on s in Subjects with Critical Limb Ischemia B elow- t he- K nee (AMBITION BTK). AMBITION BTK is a prospective, multicenter, randomized controlled trial (RCT) designed to investigate the clinical safety and effectiveness of the Auryon Atherectomy System combined with standard balloon angioplasty, compared to balloon angioplasty alone, in treating infrapopliteal lesions in patients with Critical Limb Ischemia (CLI). The primary endpoint will be evaluated using a win-ratio approach, comparing the two treatment groups based on the following components in a hierarchical manner at 12 months: freedom from major amputation, freedom from clinically driven target lesion revascularization (CD-TLR), and primary patency. The RCT will include up to 224 patients at up to 30 sites. In parallel, a companion registry will enroll up to 1,500 additional patients who are ineligible for the RCT and are treated with the Auryon System above or below the knee. 'The enrollment of the first patient in the AMBITION BTK trial is a significant milestone in our commitment to advancing clinical evidence for the treatment of below-the-knee peripheral artery disease (PAD),' said Laura Piccinini, Senior Vice President/General Manager, Cardiovascular & International, AngioDynamics. 'There is a pressing need for new treatment strategies to help patients suffering from chronic limb ischemia, and we are proud to partner with clinicians to evaluate the Auryon System in this important setting.' The overall risk of limb loss in CLI is estimated at 20–25% at one year if left untreated, reflecting a large impact on quality of life and healthcare costs. 1 Incidence of infrapopliteal disease in patients with CLI, particularly in the diabetic population, is estimated to be >70%. 2 'Treatment options for below-the-knee lesions are still limited and often depend heavily on balloon angioplasty,' said AMBITION BTK Co-Principal Investigator Ehrin Armstrong, FACC, FSCAI, FSVM, MD, MSc, Interventional Cardiologist and Vascular Disease, Director of Clinical Research, Advanced Heart and Vein Center. 'The Auryon laser can restore laminar flow and therefore has the potential to improve outcomes in this challenging patient population significantly.' The first patient in the trial was treated by Anahita Dua, MD, MS, MBA, FACS, a vascular surgeon at Massachusetts General Hospital and associate professor of Surgery at Harvard Medical School, and Co-Principal Investigator of AMBITION BTK. 'I'm excited to perform the first patient case in the AMBITION BTK study. Patients with below-the-knee disease often face limited treatment options and poor long-term outcomes,' said Dr. Dua. 'Across the world, there has been a significant increase in patients with below-the-knee (BTK) disease, which is, unfortunately, resulting in an amputation epidemic. Having new tools and techniques to restore blood flow to the foot, allowing wounds to heal, and patients to preserve both their limbs and lives, is critically important and the focus of this trial. This trial will allow us to collect high-quality, real-world data using a robust research design, helping us truly evaluate the impact of laser technology in BTK disease.' The Auryon laser can be used to treat all infrainguinal lesion types, including above-the-knee (ATK), BTK, and In-Stent Restenosis (ISR) 3,4,5,6 and, to date, it has been used to treat more than 100,000 patients in the United States and worldwide. 7 Visit and for more information about the AMBITION BTK RCT and Registry. For important risk information, visit About the Auryon Atherectomy System The Auryon Atherectomy System uses innovative technology to deliver powerful treatment of arterial occlusions. The Auryon Atherectomy System is the first laser atherectomy system to efficiently treat any lesion type, any lesion length, at any lesion location, with minimal impact on vessel walls. 3,5,8,9 The Auryon Atherectomy System uses solid-state laser technology for the treatment of PAD and is FDA cleared with an indication for treatment, including atherectomy, of infrainguinal stenoses and occlusions, including ISR. 4,6 The Auryon System's targeted biological reactions minimize the risk of perforation and preserve the ability to vaporize lesions without thermal ablation. 3,5,8,9 The Auryon System uses a 355nm wavelength laser platform which enables the use of longer wavelengths and shorter pulses to produce a groundbreaking delivery of short UV laser pulses. 4 For more information, please visit About AngioDynamics, Inc. AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life. The Company's innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit Safe Harbor This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as 'expects,' 'reaffirms,' 'intends,' 'anticipates,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'projects,' 'optimistic,' or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign healthcare reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2025. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason. AngioDynamics, the AngioDynamics logo and Auryon are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. All other trademarks are property of their respective owners. 1 2 3 Rundback J, Chandra P, Brodmann M, Weinstock B, Sedillo G, Cawich I, et al. Novel laser-based catheter for peripheral atherectomy: 6-month results from the Eximo Medical B-LaserTM IDE study. Catheter Cardiovasc Interv. 2019;1-8. 4 Auryon System Indications for Use 5 Shammas NW, Chandra P, Brodmann M, Weinstock B, Sedillo G, Cawich I, et al. Acute and 30-day safety and effectiveness evaluation of Eximo Medical's B-LaserTM, a novel atherectomy device, in subjects affected with infrainguinal peripheral arterial disease: Results of the EXPAD-03 trial. Cardiovas Revasc Med. 2020;21(1):86-92 6 Built-in aspiration available only with the 2.0- and 2.35-mm catheters. 7 AngioDynamics' J.P. Morgan Healthcare Conference Presentation Published 2025. 8 Herzog A, Bogdan S, Glikson M, Ishaaya AA, Love C. Selective tissue ablation using laser radiation at 355 nm in lead extraction by a hybrid catheter; a preliminary report. Lasers Surg Med. 2016;48(3):281-287 9 Vogel A, Venugopalan V. Mechanisms of pulsed laser ablation of biological tissues. Chem Rev. 2003;103(2):577-644 Expand
Business Wire
3 hours ago
- Business Wire
Hyperfine Swoop ® AI-Powered Portable MRI System Demonstrates 100% Sensitivity for ARIA-E Detection in New Data Presented at the 2025 Alzheimer's Association International Conference
TORONTO--(BUSINESS WIRE)-- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop ® system—announced promising early results from the CARE PMR (Capturing ARIA Risk Equitably with Portable MR) study presented at the 2025 Alzheimer's Association International Conference in Toronto, Canada. The Swoop® system achieved 100% sensitivity in detecting mild to moderate ARIA-E, a condition marked by cerebral edema. Share Researchers from the Benzinger Lab at Washington University School of Medicine in St. Louis reported interim results from 31 Alzheimer's patients undergoing Lecanemab therapy. Participants were scanned using the Swoop ® system within one week of their clinical high-field MRI scans, as part of the safety monitoring protocol required by the FDA when it approved Lecanemab. The Swoop ® system achieved 100% sensitivity in detecting mild to moderate ARIA-E, a condition marked by cerebral edema. Researchers note that while ultra-low-field MRI is promising as a triage tool to screen for ARIA-E, high-field MRI may remain necessary for comprehensive evaluation in some cases. Appropriate use guidelines for amyloid-targeting therapies, including Lecanemab and Donanemab, require MRI safety monitoring at multiple, specific intervals throughout the course of therapy. However, regular screening with conventional MRI systems is often hindered by high costs, scheduling delays, and logistical challenges for both patients and caregivers. The Swoop ® system addresses these barriers by offering an affordable, portable imaging solution that is readily available to patients at the point of care, such as neurology offices and infusion clinics. Dr. Tammie Benzinger, principal investigator of the study, noted, 'This research could help alleviate the burden on families and facilities and improve overall access to care. We are hoping to expand the project to Washington University's Medical Campus to include community sites offering infusion therapy for early Alzheimer's disease.' These findings from the CARE PMR study underscore the potential of portable MRI to transform ARIA-E monitoring and expand access to care. The Swoop ® system enables clinicians to confidently detect ARIA-E, while offering patients and caregivers the convenience of point-of-care screening, eliminating the need for separate imaging appointments. 'We are proud to collaborate with leading clinicians and researchers who share our vision of advancing Alzheimer's care through accessible innovation,' said Edmond Knopp, MD, Chief Medical Officer at Hyperfine. The CARE PMR study is a collection of data from multiple sites assessing the clinical utility and workflow benefits of using Swoop ® system images to detect amyloid-related imaging abnormalities (ARIA) in Alzheimer's patients receiving amyloid-targeting therapy. It is funded by the Alzheimer's Association and the American Society of Neuroradiology. For more information about the Swoop ® system, please visit About the Swoop ® Portable MRI Systems The Swoop ® Portable MR Imaging ® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. About Hyperfine, Inc. Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop ® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop ® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine, Inc. Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the 'Company') may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop ® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under 'Risk Factors' therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Yahoo
11 hours ago
- Yahoo
Android phones helping detect potential earthquakes
(NewsNation) — More and more every day, it seems like smartphones can expand our knowledge on everything, including detecting potential earthquakes. Earthquakes? Yes. Recently, researchers from Google and partner institutions shared results from the Android Earthquake Alerts system. The AEA, over the last three years, has expanded earthquake warning coverage from 250 million people to 2.5 billion in 98 countries. The system sends a signal to Google's earthquake detection server, and the possible location where the shaking occurs. It then analyzes data from phones to confirm that an earthquake is happening, while also estimating its location and magnitude. Two alerts are then sent out: BeAware and TakeAction. Alaska is the most earthquake-prone state. Here is why Wednesday's earthquake was notable 'The system has now detected over 18,000 earthquakes, from small tremors of M1.9 to major quakes reaching M7.8,' according to the research. 'For the events significant enough to warn people, alerts were issued for over 2000 earthquakes, culminating in 790 million alerts being sent to phones worldwide.' 'The impact has been a ~10x change in the number of people with access to EEW systems.' Dating back to March 31, 2024, AEA has issued alerts to Android phones for a total of 1279 events that were detected. Only three were false alarms, with two resulting from thunderstorms. Android phones make up more than 70% of the world's smartphones as of July 2025. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
